Table1.
Clinical and molecular characteristics of cohort study lesions
| IBD control |
LGD-IBD | SEC | SSA/P | P-value* | |
|---|---|---|---|---|---|
| N | 44 | 29 | 19 | 10 | |
| Median age, years (IQR) | 56 (52–60) | 58 (51–61) | 60 (53–64) | 48 (42–57) | 0.16 |
| Males, n (%) | 18 (41%) | 15 (52%) | 15 (79%) | 7 (70%) | 0.03 |
| CUC, n (%) | 34 (77%) | 20 (69%) | 14 (74%) | 4 (40%) | 0.13 |
| Median IBD duration at index, years (IQR) | 21 (13–30) | 12 (6–21) | 23 (11–31) | 10 (2–22) | 0.03 |
| Extensive disease, n (%) | 37 (84%) | 26 (90%) | 14 (74%) | 7 (70%) | 0.36 |
| PSC, n (%) | 10 (23%) | 6 (21%) | 7 (37%) | 0 (0%) | 0.16 |
| Median lesion size, mm (IQR) | - | 3 (1–8.5) | 1 (1–3) | 4.5 (4–6.25) | 0.01 |
| mBMP3+, n (%) | 5 (11%) | 4 (14%) | 9 (47%) | 8 (80%) | <0.0001 |
| mNDRG4+, n (%) | 4 (9%) | 12 (41%) | 12 (63%) | 8 (80%) | <0.0001 |
| KRAS+, n (%)** | 6/42 (14%) | 6/28 (21%) | 6/12 (50%) | 1/8 (13%) | 0.06 |
| Any marker+, n (%) | 10 (23%) | 16 (55%) | 15 (79%) | 9 (90%) | <0.0001 |
*
Trend across all groups
**
KRAS mutations could not be assayed in all samples
CRN, colorectal neoplasia; CUC, chronic ulcerative colitis; IBD, inflammatory bowel disease; IQR, inter-quartile range; LGD, low-grade dysplasia; PSC, primary sclerosing cholangitis; SEC, serrated epithelial change, SSA/P, sessile serrated adenoma/polyp